RJRita de Jesus

Rita de Jesus

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rita de Jesus has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Alexandra Ramos Fernandes

    Associate Laboratory i4HB – Institute for Health and Bioeconomy, NOVA School of Science and Technology, NOVA University Lisbon, 2819-516 Caparica, Portugal

    1 shared publication
  • Bernardo Braga

    Department of Chemistry LAQV REQUIMTE Associated Laboratory from Green Chemistry NOVA School of Science and Technology, NOVA FCT Caparica Portugal

    1 shared publication
  • Celina Schenkelberger

    Departamento de Ciências da Vida Associate Laboratory i4HB ‐ Institute for Health and Bioeconomy NOVA School of Science and Technology, NOVA, University Lisbon Caparica Portugal

    1 shared publication
  • Daniela Peixoto

    B’s Research Group, I3Bs-Research Institute on Biomaterials, Biodegradable and Biomimetics, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, University of Minho, AvePark, Parque de Ciência e Tecnologia, Rua Ave 1, Edifício 1 (Sede), 4805-694 Barco, Guimarães, Portugal

    1 shared publication
  • João Aires-De-Sousa

    LAQV REQUIMTE, Chemistry Department, NOVA School of Science and Technology, NOVA-FCT, NOVA University Lisbon, Caparica, Portugal

    1 shared publication
  • Luisa Maria Ferreira

    LAQV‐REQUIMTE, Chemistry Department NOVA School of Science and Technology (NOVA FCT) Caparica Portugal

    1 shared publication

Latest Publications

  • Open Access

    Synthesis and Biological Activity of Novel Aromatic Aminopropyl Lactams in Two Cancer Cell Models

    by M. Margarida Martins, Ruben Valente, Ruben Amaro, Maria S. Viana, Rita de Jesus, Bernardo Braga, Daniela Peixoto, Celina Schenkelberger, Matilde Simão, Pedro V. Baptista, et al.

    The development of new therapeutic agents for glioblastoma and hepatocellular carcinoma (HCC) remains a priority due to poor prognosis, limited treatment options, and high recurrence rates. Herein, we report a one‐pot synthesis of aromatic aminopropyl lactams (ArAPLs) via hydrolysis of bicyclic amidines (DBN, DBU), followed by reductive amination with aromatic aldehydes. These compounds were designed to target histamine H 3 receptors (H 3 R), which are often overexpressed in these malignancies. Docking studies suggested that compounds 3a and 4a may act as H 3 R antagonists, showing favorable binding through hydrophobic and hydrogen‐bonding interactions. Biological evaluation identified 3a and 4a as the most promising compounds, exhibiting micromolar antiproliferative activity in glioblastoma and HCC cell models. Compound 3a showed the best balance between potency and selectivity, including activity in 3D spheroid models and modulation of cell cycle‐related markers. In coculture systems, spheroids displayed reduced size and density, although a slight increase in viability was observed, particularly with 4a . Variations in peripheral cell layers suggest a role for macrophage behavior. Overall, these findings support the cytotoxic potential of ArAPLs, although further studies are required to confirm their role as H 3 R antagonists.